Available in blisters, 10 pieces in 1 cardboard package. The white powder is portioned into soluble capsules.
Maxilak belongs to the group of multicomponent probiotic complexes of the 3rd generation, including several strains of live bifidobacteria and lactobacilli, which enhance each other’s activity and have a corrective effect on the digestive processes. In addition, the beneficial bacteria included in the composition suppress the proliferation of pathogens, minimizing the risk of developing diseases of the gastrointestinal tract.
Compound
| Capsules | 1 caps. |
| active substances: | |
| lyophilisate of probiotic bacteria* | >4.5 109 CFU |
| fructooligosaccharides (prebiotic component) | 63 mg |
| excipients: microcrystalline cellulose; magnesium stearate; silica; titanium dioxide; hypromellose | |
| *Contents of components in a daily dose (see table) |
Table
| Component | Amount per daily serving: 1 capsule. weighing (325±16.3) mg |
| Active substances | |
| Probiotic microorganisms | |
| Bifidobacteria | |
| Bifidobacterium longum | 6.75 108 CFU |
| Bifidobacterium breve | 4.5 108 CFU |
| Bifidobacterium bifidum | 2.25 108 CFU |
| Total | 1.35 109 CFU |
| Lactobacilli | |
| Lactobacillus acidophilus | 9 108 CFU |
| Lactobacillus rhamnosus | 4.5 108 CFU |
| Lactobacillus plantarum | 2.25 108 CFU |
| Lactobacillus casei | 2.25 108 CFU |
| Total | 1.8 109 CFU |
| Lactic acid microorganisms | |
| Lactococcus lactis | 9 108 CFU |
| Streptococcus thermophilus | 4.5 108 CFU |
| Total | 1.35 109 CFU |
| Excipients | |
| Fructooligosaccharides | 63 mg |
Reviews
Reviews about Maxilak from users Most reviews (about 80-85 percent) about Maxilak are positive, which allows us to judge the high effectiveness of the drug. Patients who left positive reviews about the dietary supplement used it to normalize intestinal function, relieve diarrhea, eliminate constipation, treat infectious pathologies, and prevent dysbiosis during antibiotic therapy. In all of these situations, the drug turned out to be effective.
As for negative reviews about Maxilac, there are very few of them. Patients complained of poor tolerability of the supplement and the occurrence of allergic reactions, which made further use of the drug impossible. In some cases, negative reviews were left by people who considered the cost of the dietary supplement to be too high.
As for doctors, they speak positively about Maxilak. According to them, the supplement effectively and quickly eliminates dyspeptic symptoms caused by functional disorders of the intestine, eliminates dysbiosis, and also normalizes stool and digestion. Doctors consider the main advantages of the drug to be its rapid clinical effect and the possibility of using the supplement in patients of any age and gender.
To study reviews about Maxilak, go to the end of the article. If you have your own opinion about the supplement, share it with other site visitors. Believe me: they will thank you for it.
Characteristic
Dietary supplement Maxilak® is a freeze-dried strain of probiotic bacteria, so the color of the substance in the capsule can be light or dark cream. It is acceptable to have darker, brown or black color shades of the capsule contents. This coloring occurs as a result of the encapsulation process and is not a deviation from the norm.
Special protection SFERA (SURROUNDED FREEZE RELEASE ARMOR)
promotes the preservation of beneficial bacteria in the Maxilac® dietary supplement. The bacteria present in Maxilac® are protected from the acidic contents of gastric juice, bile salts and digestive enzymes. Most of the probiotic bacteria enter the intestines and are not destroyed in the stomach, which has a positive effect on the restoration of the microflora of the gastrointestinal tract (GIT).
Maxilac: how long to take
One capsule of Maxilac contains such a quantity of beneficial bacteria that to normalize the functioning of the digestive system, it is enough to take 1 capsule per day. Until the size of the bacterial colonies reaches the desired value, the microorganisms introduced using capsules will play the role of the natural flora of the large and small intestines.
The duration of taking the drug directly depends on the condition that caused the microflora imbalance. If the problem arose while taking antibiotics, then Maxilac should be used for at least 14 days after completion of treatment. It is recommended to start taking the symbiotic from the first day of the course of antibiotic therapy. This will reduce the time allotted for restoring the functioning of the digestive system and reduce the number of negative reactions of the body to the antibiotic.
If you become infected with intestinal infections, you should start a course of Prim Maxilac immediately after the cessation of symptoms such as diarrhea, vomiting and fever. The duration of treatment in this case lasts from 7 to 10 days.
Component Properties
Synbiotic (probiotic + prebiotic) Maxilak® is a complex of probiotic (9 strains of lacto- and bifidobacteria in a concentration of 4.5·109 CFU in each capsule) and prebiotic (fructooligosaccharides) components for the correction of imbalances in the gastrointestinal microflora, incl. caused by taking drugs.
Probiotics are beneficial live microorganisms that have a beneficial effect on the body by normalizing the composition or increasing the activity of normal intestinal microflora.
Prebiotics are food ingredients that have a beneficial effect on the human body as a result of selective stimulation of growth and/or increase in the biological activity of normal intestinal microflora.
Synbiotics are ingredients that are a combination of pro- and prebiotics. They have a mutually reinforcing effect on metabolic processes in the human body.
The lactobacteria contained in Maxilak® suppress the growth of pathogenic microflora, process lactose into simple sugars, which is useful for people with lactase deficiency, intolerance to milk and dairy products.
Bifidobacteria, which are also included in Maxilak®, support normal processes of parietal digestion and suppress the growth of pathogenic microflora
Fructooligosaccharides stimulate the rapid proliferation of beneficial bacteria and inhibit the development of pathogenic bacteria of external origin, reduce intestinal contamination with toxins and improve its functioning, stimulate peristalsis, cleanse toxins, and serve to prevent constipation, diarrhea, and improve gastrointestinal functions.
Is it possible to use Maxilac during pregnancy?
Pregnant women are not contraindicated in taking Maxilac, since beneficial bacteria do not harm the fetus, but only help maintain the normal state of microflora in the mother’s intestines.
In addition, Maxilak is indicated for pregnant women who have problems with bowel movements. A common problem for women in an interesting position is constipation, which is associated both with the restructuring of the body and with the restrained condition of the intestines. The child is constantly growing and actively moving his legs and arms, limiting intestinal motility. This leads to the development of constipation. Maxilac helps the digestive organ process food and form soft stools, which are easier to move to the exit even in cramped conditions.
When a woman is plagued by toxicosis in the early stages, the doctor may prescribe Maxilac as a remedy for nausea. The body does not have to waste its energy processing food. Capsules carrying beneficial bacteria quickly cope with the breakdown of food products, allowing them to be absorbed into the blood in a timely manner.
Another important factor in prescribing Maxilac for pregnant women is the prevention of thrush. Every pregnant woman knows that the period of bearing a child is closely related to the suppression of one’s own immunity and the restructuring of hormonal levels, which is why candidiasis often occurs, tormenting the woman with unpleasant sensations. Taking Maxilac allows you to restrain the fungi living in the intestines, preventing them from multiplying and causing thrush.
Recommended
As a dietary supplement - a source of probiotic microorganisms, including:
- as a means to normalize intestinal microflora during and/or after taking medications that can cause changes in the qualitative and/or quantitative composition of the gastrointestinal microbiocenosis;
- as an aid for functional intestinal disorders, diarrhea (diarrhea), indigestion, constipation, flatulence (bloating), nausea, belching, vomiting, pain and discomfort in the abdomen;
— during seasonal surges of infectious diseases (to support immunity);
- as a prevention of intestinal disorders when changing climate and place of stay.
Which is better Maxilac or Baktistatin
Baktistatin, unlike Maxilac, contains not only bacteria beneficial to the intestines, but also a sorbent. This suggests that in case of poisoning and intestinal infections, it is more reasonable to use Baktistatin. It introduces strains of beneficial bacteria into the affected digestive system and, using a sorbent, collects and removes toxins that lead to a worsening of the condition. The third important component of Baktistatin is a set of metabolites - enzymes that facilitate the task of the pancreas and liver. Once in the duodenum, Baktistatin enzymes break down fats and proteins, relieving the load on the digestive organs.
The disadvantage of Baktistatin is the release form - these are capsules, and children under 6 years old cannot take this drug. In addition, Bactistatin is prohibited for use by pregnant and lactating women.
Manufacturer
Manufacturer: DANISCO France SAS ZA de Buxieres BP 10, 86220, DANGE-SAINT-ROMAIN, France.
Importer: ZAO Danisko, 121614, Russian Federation, Moscow, st. Krylatskaya, 17, bldg. 3.
Organization authorized to accept claims from consumers: JSC FP Obolenskoye, 142279, Russian Federation, Moscow region, Serpukhovsky district, urban settlement. Obolensk, r.p. Obolensk, district of the settlement Obolensk, industrial zone, p. 78.
Tel/fax
www.maxilac.ru
Moximac solution for infusion 400 mg/250 ml, 250 ml bottle, 1 pc.
The benefits of treatment with moxifloxacin, especially in cases of non-severe infections, must be assessed taking into account the information contained in this section.
Prolongation of the QTc interval and clinical conditions under which prolongation of the QTc interval is possible
It has been established that moxifloxacin in some patients leads to a prolongation of the QTc interval on the electrocardiogram. The degree of QT prolongation may increase with increasing plasma concentrations of the drug during rapid infusion. Therefore, recommendations for infusion duration should be followed, which should be at least 60 minutes and not exceed the intravenous dose. 400 mg 1 time per day. For more information, see the sections “Contraindications” and “Interaction with other drugs and other types of interactions.”
Moxifloxacin therapy should be discontinued if symptoms associated with cardiac arrhythmia occur, regardless of whether this is confirmed by ECG results.
Moxifloxacin should be used with caution in patients with conditions predisposing to the development of arrhythmias (for example, acute myocardial ischemia), since such patients have an increased risk of ventricular arrhythmias (including torsades de pointes) and cardiac arrest (see also sections "About" Interaction with other drugs and other types of interactions"). Moxifloxacin should be used with caution in patients taking medications that may reduce potassium levels (see also sections “Contraindications” and “Interaction with other drugs and other types of interactions”).
Moxifloxacin should be administered with caution to patients receiving medications associated with clinically significant bradycardia (see also Contraindications section).
Women and elderly patients may be more sensitive to the effects of drugs that prolong the QTc interval, such as moxifloxacin, so such patients require special attention.
Hypersensitivity/allergic reactions
Cases of hypersensitivity and allergic reactions have been reported after the first use of fluoroquinolones, including moxifloxacin. Anaphylactic reactions can take the form of life-threatening shock even after the first use of the drug. If severe hypersensitivity reactions occur clinically, moxifloxacin should be discontinued and appropriate treatment (eg, shock therapy) should be initiated.
Severe liver dysfunction
Cases of fulminant hepatitis have been reported with the use of moxifloxacin, which can lead to liver failure (including deaths) (see Adverse Reactions). If symptoms of fulminant hepatitis occur, such as rapidly developing asthenia accompanied by jaundice, dark urine, bleeding tendency or hepatic encephalopathy, patients are advised to consult a doctor before continuing treatment.
If signs of liver dysfunction occur, a liver function test should be performed.
Severe bullous skin reactions
Cases of bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with the use of moxifloxacin (see section "Adverse reactions"). If reactions occur on the skin and/or mucous membranes, patients are advised to immediately consult a doctor before continuing treatment.
Patients prone to seizures
Quinolones are known to cause seizures. They should be used with caution in patients with central nervous system disorders or other risk factors that may precipitate seizures or lower the seizure threshold. If seizures occur, stop using moxifloxacin and take appropriate measures.
Peripheral neuropathy
Cases of sensory or sensorimotor polyneuropathy resulting in paresthesia, hypoesthesia, dysesthesia, or weakness have been reported in patients receiving quinolones, including moxifloxacin. Patients using moxifloxacin are advised to inform their physician if they develop symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness before continuing treatment to prevent the development of irreversible conditions (see “Adverse Reactions”).
Reactions from the psyche
Psychiatric reactions may occur even after the first use of fluoroquinolones, including moxifloxacin. In rare cases, depression or mental reactions have progressed to the development of suicidal thoughts and manifestations of self-injury such as suicide attempts (see section "Adverse Reactions"). If a patient develops such reactions, treatment with moxifloxacin should be discontinued and appropriate measures taken. Caution should be exercised when prescribing moxifloxacin to patients with a history or current history of mental illness.
Antibiotic-associated diarrhea, including colitis
Cases of antibiotic-associated diarrhea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and Clostridium difficile-associated diarrhea, have been observed in association with the use of broad-spectrum antibiotics, including moxifloxacin. The severity of these phenomena can range from mild diarrhea to fatal colitis. It is therefore important to consider the possibility of such a diagnosis in patients who develop severe diarrhea during or after use of moxifloxacin. If AAD or AAC is suspected or confirmed, treatment with antimicrobial agents, including moxifloxacin, should be discontinued and appropriate therapeutic measures initiated immediately. In addition, appropriate infection control measures must be taken to reduce the risk of transmission. Antimotility medications are contraindicated in patients who develop severe diarrhea.
Patients with myasthenia gravis.
Moxifloxacin should be used with caution in patients with myasthenia gravis as its symptoms may be exacerbated.
Tendon inflammation, tendon rupture
During therapy with quinolones, including moxifloxacin, inflammation and rupture of tendons (especially the Achilles tendon), sometimes bilateral, may occur, developing even 48 hours after the start of treatment and may continue for several months after cessation of treatment. The risk of tendinitis and tendon rupture increases in older patients and in patients receiving concomitant treatment with corticosteroids. If pain or inflammation occurs, use of moxifloxacin should be discontinued, the injured limb should be offloaded, and a physician should be contacted immediately to initiate appropriate treatment (e.g., immobilization) of the affected tendon (see sections “Contraindications” and “Adverse Reactions”).
Patients with impaired renal function
Elderly patients with renal impairment should be given moxifloxacin with caution if they are unable to maintain adequate fluid levels, as dehydration increases the risk of renal failure.
From the organs of vision
In case of deterioration of vision or any effect on the visual organs, you should immediately seek advice from an ophthalmologist (see sections “The ability to influence the speed of reaction when driving vehicles or other mechanisms”, “Adverse reactions”).
Dysglycemia
As with all fluoroquinolones, cases of abnormal blood glucose levels, both hypoglycemia and hyperglycemia, have been reported during treatment with moxifloxacin. Dysglycemia developed predominantly in elderly patients with diabetes who received oral hypoglycemic agents (for example, sulfonylureas) or insulin simultaneously with treatment with moxifloxacin. Patients with diabetes are advised to carefully monitor blood glucose levels (see section "Adverse Reactions").
Prevention of photosensitivity reactions
When using quinolones, photosensitivity reactions were recorded in patients. However, according to studies, when using moxifloxacin, the risk of inducing photosensitivity reactions was low. In any case, patients should avoid exposure to prolonged and/or intense sunlight or ultraviolet radiation during treatment with moxifloxacin.
Patients with glucose-6-phosphate dehydrogenase deficiency
Patients with deficiency of glucose-6-phosphate dehydrogenase activity, as well as patients with a family history of this pathology, are prone to the development of hemolytic reactions during treatment with quinolones. Therefore, moxifloxacin should be used with caution in this category of patients.
Inflammation of tissue in the periarterial zone
Moxifloxacin, solution for infusion, is intended for intravenous use only. Intra-arterial administration should be avoided, since tissue inflammation in the periarterial zone has been observed in preclinical studies with this route of administration.
Patients with specific complicated infections of the skin and subcutaneous tissue.
The clinical effectiveness of moxifloxacin in the treatment of severe infections associated with burns, fasciitis and infected diabetic foot accompanied by osteomyelitis has not been established.
Patients on a salt-controlled diet
The drug contains 787 mg (about 34 µmol) sodium per dose. Patients on a salt-controlled diet should take this fact into account.
Impact on biological tests
Moxifloxacin may interfere with test results for Mycobacterium spp. by inhibiting mycobacterial growth, which, in turn, can lead to false negative results in patients taking moxifloxacin.
Patients with methicillin-resistant Staphylococcus aureus (MRSA) infections
Moxifloxacin is not recommended for the treatment of infections caused by methicillin-resistant Staphylococcus aureus. If there is suspicion or confirmation of an infection caused by MRSA, it is necessary to begin treatment with an appropriate antibacterial drug (see section "Pharmacodynamics").
Interaction with other drugs
The drug enhances the effects of monoamine oxidase inhibitors, sedatives, and ethanol.
The risk of developing the hepatotoxic effect of paracetamol increases with simultaneous use of ethanol, hepatotoxic drugs, inducers of microsomal oxidation enzymes in the liver (phenytoin, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants, etc.).
Concomitant use of paracetamol in high doses increases the effect of anticoagulant drugs (decreased synthesis of procoagulant factors in the liver). Paracetamol reduces the effectiveness of uricosuric drugs.
Long-term use of barbiturates reduces the effectiveness of paracetamol. Metoclopramide and domperidone increase, and cholestyramine reduces the rate of absorption of paracetamol. Inhibitors of microsomal oxidation enzymes (including cimetidine) reduce the risk of hepatotoxic action of paracetamol.
The simultaneous use of ethanol and paracetamol contributes to the development of acute pancreatitis. Long-term combined use of paracetamol and nonsteroidal anti-inflammatory drugs increases the risk of developing “analgesic” nephropathy and renal papillary necrosis, and the onset of end-stage renal failure. Simultaneous long-term administration of paracetamol in high doses and salicylates increases the risk of developing kidney or bladder cancer. Diflunisal increases the plasma concentration of paracetamol by 50%, the risk of developing hepatotoxicity. Myelotoxic drugs enhance the hematotoxicity of paracetamol.
Phenylephrine reduces the hypotensive effect of diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine), and reduces the antianginal effect of nitrates.
Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the hypertensive effect of pheniramine. Monoamine oxidase inhibitors (including furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the vasoconstrictor effect and arrhythmogenicity of phenylephrine; arterial hypertension is possible against the background of reserpine. Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect of pheniramine.
Inhalational anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias. Thyroid hormones increase (mutually) the effect of phenylephrine and the associated risk of coronary insufficiency (especially in coronary atherosclerosis).
Ascorbic acid increases the concentration of benzylpenicillin and tetracyclines in the blood, reduces the effectiveness of heparin and indirect anticoagulants, increases the overall clearance of ethanol, which in turn reduces the concentration of ascorbic acid in the body, reduces the therapeutic effect of antipsychotic drugs (neuroleptics) phenothiazine derivatives, tubular reabsorption of amphetamine and tricyclics antidepressants.
When used simultaneously with acetylsalicylic acid, the urinary excretion of ascorbic acid increases and the excretion of acetylsalicylic acid decreases. Acetylsalicylic acid, oral contraceptives, fresh juices and alkaline drinks reduce the absorption and absorption of ascorbic acid.
Ascorbic acid improves the absorption of iron preparations in the intestine; increases the risk of developing crystalluria during treatment with salicylates and short-acting sulfonamides, slows down the excretion of acids by the kidneys, increases the excretion of drugs that have an alkaline reaction (including alkaloids), reduces the concentration of oral contraceptives in the blood, and reduces the chronotropic effect of isoprenaline. With long-term use or use in high doses, it can interfere with the interaction of disulfiram and ethanol; in high doses, it increases the excretion of mexiletine by the kidneys.
Quinoline drugs, calcium chloride, salicylates, and glucocorticoids deplete ascorbic acid reserves when used for a long time. Barbiturates and primidone increase the excretion of ascorbic acid in the urine.
